Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model

Fig. 5

Levels of extracellular amyloid-β we are only measuring the amyloid burden and not the rest of A burden, intracellular paired helical filament (PHF) burden, and soluble Aβ or hyperphosphorylated tau (p-tau) in brains from 19-month-old triple-transgenic (3 × Tg) mice infused with GW-23B7 or control vehicle alone. a Immunohistochemistry of representative GW-23B7- or vehicle control-infused 3 × Tg mouse brains showing hippocampus and subiculum amyloid plaques as detected by specific antibodies 4G8/6E10 or intraneuronal PHF as detected by commercial antibody PHF-1. Scale bars for 4G8/6E10 hippocampus images represent 50 μm, and scale bars for 4G8/6E10 subiculum images represent 100 μm. Scale bars for insets are 10 μm. Scale bars for PHF-1 images represent 200 μm. b Quantitation of the amyloid and tau burden for each group of infused animals characterized in (a). *p < 0.05 and **p < 0.01. No significant differences in intracellular PHF-1 burden were found. c Levels of soluble Aβ1–40, Aβ1–42, human aggregated Aβ, threonine 231 phosphorylated tau, and total tau in supernatants from 20% brain homogenates of the GW-23B7- and vehicle-infused 3 × Tg mice groups. *p < 0.05 and **** p < 0.0001

Back to article page